Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BELINDA SAVAGE-EDWARDS

NPI
1558341164
CMS profile
25195
Location
HUNTSVILLE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$29,588.80

101 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BELINDA SAVAGE-EDWARDS

NPI 1558341164 · CMS profile ID 25195

HUNTSVILLE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558341164?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BELINDA SAVAGE-EDWARDS, NPI 1558341164, CMS profile ID 25195. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558341164?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BELINDA SAVAGE-EDWARDS, NPI 1558341164, CMS profile ID 25195. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558341164?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BELINDA SAVAGE-EDWARDS, NPI 1558341164, CMS profile ID 25195, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1558341164?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

101 matching records · $29,588.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 101 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 101.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $0.1805/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807360799 CMS
UCB, Inc. $0.5905/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807360805 CMS
UCB, Inc. $21.5705/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807360795 CMS
Alexion Pharmaceuticals, Inc. $19.9305/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124341 CMS
Lilly USA, LLC $11.4205/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937108455 CMS
Lilly USA, LLC $950.0005/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937106093 CMS
UCB, Inc. $2.3304/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807353939 CMS
Biohaven Pharmaceuticals, Inc. $75.4904/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852615383 CMS
Biohaven Pharmaceuticals, Inc. $1,275.0004/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852615385 CMS
UCB, Inc. $18.5104/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807353797 CMS
Lilly USA, LLC $950.0004/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937108451 CMS
Lilly USA, LLC $950.0004/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937108747 CMS
Biohaven Pharmaceuticals, Inc. $11.6004/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852615381 CMS
Lilly USA, LLC $950.0004/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937120273 CMS
Biogen, Inc. $12.0204/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827827211 CMS
Lilly USA, LLC $950.0004/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937107447 CMS
Amgen Inc. $21.4904/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825175959 CMS
Lilly USA, LLC $950.0004/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937120267 CMS
Currax Pharmaceuticals LLC $14.4104/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792537047 CMS
Alexion Pharmaceuticals, Inc. $1.1104/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124337 CMS
Alexion Pharmaceuticals, Inc. $1.8804/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124335 CMS
Alexion Pharmaceuticals, Inc. $19.3604/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124339 CMS
Alexion Pharmaceuticals, Inc. $5.4003/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124333 CMS
Lilly USA, LLC $2,137.5003/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937108054 CMS
Almatica Pharma LLC $19.7203/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842229473 CMS
AbbVie Inc. $11.3603/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795968921 CMS
Lilly USA, LLC $41.5003/12/2021 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937108063 CMS
Alexion Pharmaceuticals, Inc. $23.7003/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124331 CMS
SK Life Science, Inc. $15.5703/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826819969 CMS
Lilly USA, LLC $950.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937106473 CMS
UCB, Inc. $16.7503/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807434315 CMS
UCB, Inc. $0.9503/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807434321 CMS
Lilly USA, LLC $950.0003/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937106107 CMS
Lilly USA, LLC $950.0003/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937109147 CMS
Lilly USA, LLC $950.0002/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937108743 CMS
Lilly USA, LLC $950.0002/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937120281 CMS
Almatica Pharma LLC $18.4502/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842229461 CMS
UCB, Inc. $17.5702/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807433863 CMS
Avanir Pharmaceuticals, Inc. $12.5902/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801042391 CMS
AbbVie Inc. $13.6102/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795968917 CMS
Lilly USA, LLC $950.0002/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937106461 CMS
Lilly USA, LLC $950.0002/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937106469 CMS
Lilly USA, LLC $950.0001/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937106087 CMS
Lilly USA, LLC $950.0001/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937106089 CMS
Lilly USA, LLC $950.0001/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937108471 CMS
UCB, Inc. $19.5001/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807469413 CMS
Lilly USA, LLC $14.2501/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937106083 CMS
Avanir Pharmaceuticals, Inc. $16.8301/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801046495 CMS
Allergan, Inc. $750.0001/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792932911 CMS
Alexion Pharmaceuticals, Inc. $22.0201/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124323 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $26,141.84 106
PY2020 $91,067.72 186
PY2021 $29,588.80 101
PY2022 $33,867.05 123
PY2023 $2,156.21 58
PY2024 $91,078.28 154
PY2025 $21,975.09 53

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $478,136.35 51
PY2024 Principal investigator $661,469.95 48
PY2023 Principal investigator $623,746.02 38
PY2022 Recipient $12,638.00 5
PY2022 Principal investigator $357,152.00 25
PY2021 Recipient $94.00 1
PY2021 Principal investigator $302,655.00 12
PY2020 Recipient $581.49 2
PY2020 Principal investigator $81,855.75 8
PY2019 Recipient $37,730.00 1
PY2019 Principal investigator $19,798.16 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,200.00 12/31/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 years of age. No dispute reported 06/30/2026 1202532276
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202534965
Principal investigator 1 ABBVIE INC. $673.76 12/31/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age No dispute reported 06/30/2026 1202534967
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202535107
Principal investigator 1 ABBVIE INC. $500.00 12/31/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202535109
Principal investigator 1 ABBVIE INC. $1,718.60 12/04/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202527894
Principal investigator 1 ABBVIE INC. $5,717.40 12/04/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202528004
Principal investigator 1 ABBVIE INC. $7,500.00 12/04/2025 Non-covered Recipient Entity
REHAB & NEUROLOGICAL SERVICES LLC
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202528006
Principal investigator 1 ABBVIE INC. $8,925.80 11/04/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202520899
Principal investigator 1 ABBVIE INC. $11,056.50 11/04/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202520901
Principal investigator 1 Ipsen Innovation $695.00 10/30/2025 Non-covered Recipient Entity
Rehabilitation & Neurological Services, LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287274
Principal investigator 1 Ipsen Innovation $2,790.00 10/30/2025 Non-covered Recipient Entity
Rehabilitation & Neurological Services, LLC
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287276
Principal investigator 1 ABBVIE INC. $5,062.20 10/09/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202513865
Principal investigator 1 ABBVIE INC. $800.80 10/09/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202515227
Principal investigator 1 ABBVIE INC. $2,242.50 09/04/2025 Non-covered Recipient Entity
REHAB & NEUROLOGICAL SERVICES LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202509474
Principal investigator 1 ABBVIE INC. $6,887.40 09/03/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202507893
Principal investigator 1 ABBVIE INC. $2,750.00 09/03/2025 Non-covered Recipient Entity
REHAB & NEUROLOGICAL SERVICES LLC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202507895
Principal investigator 1 ABBVIE INC. $4,299.10 09/03/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202507897
Principal investigator 1 ABBVIE INC. $150.00 08/05/2025 Non-covered Recipient Entity
REHAB & NEUROLOGICAL SERVICES LLC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202501648
Principal investigator 1 ABBVIE INC. $9,287.20 08/05/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202501650
Principal investigator 1 ABBVIE INC. $800.80 08/05/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202501652
Principal investigator 1 Eli Lilly and Company $25.00 07/30/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187889144
Principal investigator 1 ABBVIE INC. $481.00 07/02/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202495417
Principal investigator 1 ABBVIE INC. $3,810.30 07/02/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202495419
Principal investigator 1 ABBVIE INC. $11,000.00 07/02/2025 Non-covered Recipient Entity
REHAB & NEUROLOGICAL SERVICES LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202495421
Principal investigator 1 ABBVIE INC. $9,795.50 06/03/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202489383
Principal investigator 1 ABBVIE INC. $2,018.90 06/03/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202489611
Principal investigator 1 ABBVIE INC. $11,884.60 05/06/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481789
Principal investigator 1 ABBVIE INC. $2,819.70 05/06/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481791
Principal investigator 1 Eli Lilly and Company $109.50 04/23/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) No dispute reported 06/30/2026 1187889946
Principal investigator 1 ABBVIE INC. $11,000.00 04/03/2025 Non-covered Recipient Entity
REHAB & NEUROLOGICAL SERVICES LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202469265
Principal investigator 1 ABBVIE INC. $10,084.10 04/03/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202469284
Principal investigator 1 ABBVIE INC. $8,035.30 04/03/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202469288
Principal investigator 1 ABBVIE INC. $150.00 04/03/2025 Non-covered Recipient Entity
REHAB & NEUROLOGICAL SERVICES LLC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202472640
Principal investigator 1 Eli Lilly and Company $6,361.00 03/25/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187889148
Principal investigator 1 ABBVIE INC. $12,463.10 03/06/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202458451
Principal investigator 1 ABBVIE INC. $6,406.40 03/06/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202458493
Principal investigator 1 ABBVIE INC. $520.00 03/06/2025 Non-covered Recipient Entity
REHAB & NEUROLOGICAL SERVICES LLC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202458497
Principal investigator 1 Eli Lilly and Company $14,078.00 02/25/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187888390
Principal investigator 1 Eli Lilly and Company $2,504.84 02/25/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1187888392
Principal investigator 1 Eli Lilly and Company $421.78 02/25/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187890248
Principal investigator 1 Eli Lilly and Company $71,228.00 02/18/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1187887862
Principal investigator 1 ABBVIE INC. $12,266.80 02/05/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202444869
Principal investigator 1 ABBVIE INC. $2,740.40 02/05/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202444963
Principal investigator 1 Eli Lilly and Company $10,446.00 02/05/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) No dispute reported 06/30/2026 1187890246
Principal investigator 1 Eli Lilly and Company $1,435.29 01/31/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 1187889568
Principal investigator 1 Eli Lilly and Company $789.98 01/31/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187889948
Principal investigator 1 Eli Lilly and Company $178,872.00 01/21/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 1187889146
Principal investigator 1 Eli Lilly and Company $4,576.00 01/21/2025 Non-covered Recipient Entity
REHABILITATION & NEUROLOGICAL SERVICES, LL
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187889944
Principal investigator 1 ABBVIE INC. $2,706.60 01/02/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202434580
Principal investigator 1 ABBVIE INC. $4,009.20 01/02/2025 Non-covered Recipient Entity
REHABILITATION AND NEUROLOGICAL SERVICES LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202434585